The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: A 13-week multicenter trial

Chest

Volumn 118, Issue 5, 2000, Pages 1294-1302

  Casaburi, Richard ^a   Briggs, Dick D ^b   Donohue, James F ^c   Serby, Charles W ^d   Menjoge, Shailendra S ^d   Witek, Theodore J ^d  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Anticholinergic; Bronchodilator; COPD; Pulmonary function; Tiotropium

Indexed keywords

BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; PLACEBO; SALBUTAMOL; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; WHEEZING; XEROSTOMIA;

EID: 0033748430     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.118.5.1294     Document Type: Article

References (25)

1. Optimal assessment and management of chronic obstructive pulmonary disease (COPD)
2. Management of chronic obstructive pulmonary disease
3. Ipratropium bromide
4. The role of anticholinergic bronchodilators in adult asthma and COPD
5. Ba 679 Br, a novel anticholinergic bronchodilator: Predicted and clinical aspects
6. Effect of Ba 679 Br: A novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways
7. Tiotropium bromide (Ba 679 Br), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease
8. Tiotropium (Ba 679) pharmacology and early clinical observations
9. Tiotropium bromide, a new long-acting antimusearinic bronchodilator: A pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD)
10. Ba 679 Br, a new long-acting antimuscarinic bronchodilator: A pilot dose-escalation study
11. Long-acting bronchodilation with once daily dosing of tiotropium (Spiriva) in stable COPD
12. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD)
13. Effective use of the HandiHaler dry powder inhalation system over a broad range of COPD disease severity
14. Fifteen year interval spirometric evaluation of the Oregon predictive equations
15. Standardization of spirometry: 1994 Update
16. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD
17. Efficacy of salmeterol xinafoate in the treatment of COPD
18. Bronchodilator response in chronic obstructive pulmonary disease
19. British Thoracic Society guidelines for the management of chronic obstructive pulmonary disease
20. The onset of spirometric response following once daily inhalation of tiotropium in patients with COPD
21. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone
22. The efficacy and safety of combination bronchodilator therapy
23. Superior efficacy of tiotropium (TIO) compared to ipratropium (IpBr) as a maintenance bronchodilator in COPD
24. Anticholinergic bronchodilators